Table 2.
Baseline characteristics of type 2 diabetes mellitus patients included in the analysis of efficacy.
| Placebo | Brimonidine | Somatostatin | |
|---|---|---|---|
| n = 123 | n = 97 | n = 120 | |
| Age (years) | 62.4 ± 7.1 | 63.7 ± 6.0 | 62.6 ± 6.6 |
| Gender (% males) | 66.1 | 66.0 | 65.0 |
| BMI (Kg/m2) | 30.8 ± 5.6 | 30.8 ± 5.3 | 31.1 ± 5.4 |
| Diabetes duration (years) | 11.6 ± 5.8 | 11.1 ± 5.5 | 11.4 ± 5.5 |
| Diabetes treatment (%) | |||
| Diet | 4.8 | 2.1 | 4.2 |
| Oral agents | 65.3 | 76.3 | 73.3 |
| Oral agents + insulin | 24.2 | 21.6 | 20.8 |
| Insulin | 5.6 | 0.0 | 1.7 |
| HbA1C (%) | 7.21 ± 0.97 | 7.22 ± 1.09 | 7.11 ± 0.92 |
| Hypertension (%) | 71.0 | 73.2 | 71.7 |
| Dyslipidemia (%) | 69.4 | 67.0 | 67.5 |
| Microalbuminuria (%) | 19.3 | 22.7 | 19.1 |
| Cardiovascular disease (%) | 19.4 | 14.4 | 21.7 |
| ETDRS 10/20-35(%) | 42.7/57.3 | 38.1/61.9 | 43.3/56.7 |
| BCVA letter score | 85.9 ± 5.2 | 86.1 ± 5.2 | 85.7 ± 4.6 |
At baseline, the serum levels of CML and LamP-1 were not associated with age, gender, BMI, duration of diabetes, fasting plasma glucose, or hemoglobin A1c (HbA1c). A direct correlation was observed between ADMA and HbA1c (r = 0.13; p = 0.016); however, as occurred with CML and Lam-P1, we did not detect any relationship between ADMA and age, gender, BMI, or duration of diabetes. BMI: body mass index; ETDRS: Early Treatment Diabetic Retinopathy Study; BCVA: best corrected visual acuity.